“ORIC Pharmaceuticals is positioning two lead candidates for major late-stage advancement in 2026, with rinzimetostat (formerly ORIC-944) set to enter its first global Phase 3 trial in metastatic castration-resistant prostate cancer in the first half of the year, and enozertinib (ORIC-114) advancing toward registrational trials in first-line non-small cell lung cancer. The company anticipates multiple data readouts in 2026, supported by a strengthened cash position extending runway into the second half of 2028, highlighting potential best-in-class profiles in addressing resistance mechanisms in these high-unmet-need oncology areas.”
Detailed Pipeline Momentum Builds Toward Pivotal Trials
ORIC Pharmaceuticals continues to make steady progress in its oncology-focused pipeline, emphasizing therapies designed to overcome resistance in hormonally driven and genetically defined cancers. The company’s two primary clinical-stage assets—rinzimetostat, an allosteric inhibitor targeting the polycomb repressive complex 2 (PRC2) via the EED subunit, and enozertinib, a brain-penetrant, orally bioavailable irreversible inhibitor of EGFR and HER2—are generating increasing attention for their differentiated properties.
In metastatic castration-resistant prostate cancer (mCRPC), rinzimetostat has shown promising early signals as a combination partner with androgen receptor (AR) pathway inhibitors. Recent Phase 1b data from dose exploration cohorts, including combinations with darolutamide and apalutamide, demonstrated PSA responses and reductions in circulating tumor DNA across dose levels. These results reinforced the compound’s potential for best-in-class efficacy and a safety profile supportive of long-term use. The company completed the dose exploration portion and selected provisional recommended Phase 2 doses: 400 mg and 600 mg once daily with darolutamide (600 mg twice daily), and 600 mg, 800 mg, and 1,200 mg once daily with apalutamide (240 mg once daily).
The ongoing dose optimization phase is actively enrolling patients to refine these combinations further. Dose optimization data are expected in the first quarter of 2026, providing additional insights into tolerability and activity before the planned launch of the first global Phase 3 registrational trial in mCRPC during the first half of 2026. A program update is anticipated in the second half of 2026 following this initiation.
This advancement builds on preclinical evidence showing synergistic activity when PRC2 inhibition is combined with AR pathway blockade, particularly in models resistant to standard therapies. The strategy targets patients who have progressed on current AR inhibitors, where resistance remains a major challenge despite advances in the field.
For non-small cell lung cancer (NSCLC), enozertinib targets specific EGFR mutations, including exon 20 insertions, HER2 exon 20 insertions, and atypical (P-loop alpha-c helix compressing or PACC) mutations, with strong brain penetration to address central nervous system involvement common in these subsets. Phase 1b data have highlighted competitive systemic and intracranial activity in patients with EGFR exon 20 and PACC mutations.
The program includes ongoing studies of enozertinib as monotherapy and in combination with subcutaneous amivantamab for EGFR exon 20 insertion mutations. A Phase 3 monotherapy dose has been selected based on these results. Key upcoming readouts include first-line NSCLC data in the second half of 2026: monotherapy in EGFR exon 20 mutations, combination with subcutaneous amivantamab in the same population, and monotherapy in EGFR PACC mutations.
Registrational development plans focus on first-line NSCLC settings with the highest unmet need, with trial initiation anticipated in 2026 for one or more of these genetically defined subgroups. This positions enozertinib as a potential option in areas where current therapies face limitations in response durability and CNS control.
The company’s sharpened focus on these registrational paths has been accompanied by operational adjustments, including reduced investment in early discovery to prioritize late-stage execution. Recent financing activities have bolstered the balance sheet, with cash and investments providing runway into the second half of 2028, extending beyond expected primary endpoint readouts from the initial Phase 3 trials of both programs.
These 2026 milestones represent critical inflection points for ORIC, as positive outcomes could validate the mechanisms and potentially introduce new standards in resistant prostate cancer and mutation-specific lung cancer. Investors and clinicians alike are watching closely for the data updates and trial starts that could drive the next phase of value creation in these therapeutic areas.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, medical advice, or a recommendation to buy or sell any securities. The information presented is based on publicly available data and company disclosures as of the latest updates.